Recruitment Target Reached | 招募人數達標

Thank you for your interest in participating. Our current recruitment target has been reached.
感謝您對參與本研究的興趣,但目前的招募人數已達標。

 


 

mRNA vaccination to boost antibodies against SARS-CoV-2 in recipients of inactivated vaccines (mBoost study)

This is an open-label clinical trial on COVID-19 vaccine booster in Hong Kong organised by the School of Public Health, the University of Hong Kong. We will offer a booster dose of a mRNA COVID-19 vaccine (Fosun/Pfizer/BioNTech-Comirnaty) to adults aged 30 years and older who have received two doses of inactivated COVID-19 vaccine (for example Sinovac or Sinopharm). Then, we will track these participants for a period of 1 year (2021 – 2022) to monitor the post-vaccination reactions and immune protection after receiving COVID-19 booster vaccination.

For details, please refer to our study website.

通過接種信使核糖核酸(mRNA)疫苗加強滅活疫苗接種後的2019冠狀病毒(SARS-CoV-2)抗體(「進護」研究計劃)

這是一項由香港大學公共衞生學院主辦,在香港本地進行的有關新冠病毒(COVID-19)疫苗加強劑的開放標籤臨床研究計劃,為曾接種兩劑滅活疫苗(如科興或國藥疫苗)的30歲或以上人士提供一劑mRNA新冠疫苗加強劑(復星/輝瑞/BioNTech-復必泰)。接著,我們將追踪參加者1年(2021 – 2022),以全面監測接種新冠疫苗加強劑後的接種反應及免疫保護。

詳情可參閱本研究網站